The Applications of Mitoxantrone and Its Liposome in Adult Acute Myeloid Leukemia

Acute myeloid leukemia (AML), a rapidly progressing hematopoietic malignancy, can only be cured hopefully by stem cells transplantation (HSCT). Before HSCT, we usually exert effects attempting certain regimens to induce these tumor death. Administered in AML patients, the classic “3 + 7” intensive induction regimen including anthracyclines and cytarabine is recommended guidelines worldwide. However, conventional consist of anthracyclines, category drug limited cumulative, dose-related, progressive myocardial damage congestive heart failure occurs when its total doses break through cut-off. Based on this background, mitoxantrone (MIT), an anthraquinone, was developed new form reduce cardiotoxicity. Meanwhile, nanomedicine, liposome (Lipo-MIT), characterized improved bioavailability toxicity. This has great therapeutic potential, but different side effects. We conclude overall history development MIT Lipo-MIT, which show controversial efficacy compared doxorubicin potential Lipo-MIT. article reviewed application forms adult patients.